Tvardi Therapeutics, Inc. (TVRD) Reports $6.1M Q3 Net Loss; Cash Runway Into Q3 2027

Tvardi reported a Q3 2026 net loss of $6.1M versus $5.5M in Q3 2025 and cash of $22.3M versus $30.8M in cash, cash equivalents and short-term investments at Dec. 31, 2025. It expects cash to fund planned operations into Q3 2027.Material DetailsContext by AI AnalystThis is a quarterly update from a…